Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:47 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 11,173 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Completed Phase 1 Interventional Results available

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

NCT00073749
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
Inotuzumab ozogamicin [CMC-544]
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
11
States / cities
Birmingham, Alabama • Chicago, Illinois • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Nov 2, 2026, 10:47 PM EST
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

NCT04442178
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • St Louis, Missouri • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 3 Interventional Results available

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

NCT02926898
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Nov 2, 2026, 10:47 PM EST
Terminated Phase 1 Interventional Results available

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

NCT05350163
View directory record Official record
Conditions
Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
Interventions
T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Biological
Lead sponsor
Guenther Koehne
Other
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

NCT03146416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers

NCT05249348
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PC14586
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Nov 2, 2026, 10:47 PM EST
Recruiting Phase 1 Interventional

A Study of CRD3874-SI in People With Solid Tumors

NCT06021626
View directory record Official record
Conditions
Sarcoma, Merkel Cell Carcinoma
Interventions
CRD3874
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Not yet recruiting No phase listed Observational

Precision Medicine for Indolent Systemic Mastocytosis (PRISM)

NCT07757893
View directory record Official record
Conditions
Systemic Mastocytosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 1 Interventional Results available

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

NCT01772004
View directory record Official record
Conditions
Solid Tumors
Interventions
Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
53
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 1 Interventional

Safety Study of MGAH22 in HER2-positive Carcinomas

NCT01148849
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer
Interventions
margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Nov 2, 2026, 10:47 PM EST
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

NCT05303636
View directory record Official record
Conditions
Change in Bone Mineral Density, Bone Loss
Interventions
drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
1,536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
27
States / cities
Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 3 Interventional

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Xcopri
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Palo Alto, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Terminated Early Phase 1 Interventional

Safety and Targeting of Anti-hk2 Antibody in mCRPC

NCT04116164
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastatic Disease
Interventions
111In-DOTA-h11B6
Drug
Lead sponsor
SpectronRX
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 1 Interventional

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

NCT00876109
View directory record Official record
Conditions
Solid Cancers
Interventions
GDC-0941
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 2, 2026, 10:47 PM EST
Withdrawn Phase 1 Interventional

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

NCT02868632
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Nov 2, 2026, 10:47 PM EST
Active, not recruiting Phase 4 Interventional

The PASTDUe Nutrition Ecosystem Project (PASTDUe)

NCT05127109
View directory record Official record
Conditions
Diet, Healthy, Food, Nutrition, Intensive Care, Abdominal Trauma, Surgery, Intra-abdominal Infection, Sepsis, Ischemic Bowel, Vascular, Penetrating Abdominal Trauma, Enteral Feeding, Oral
Interventions
Nutrition Ecosystem pathway, Comparator
Combination Product · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Assessing Speech Perception and Amplification Benefit During Infancy

NCT05653999
View directory record Official record
Conditions
Hearing Loss, Children With Hearing Differences, Amplification, Speech Perception
Interventions
Hearing Aids
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 36 Months
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 1Phase 2 Interventional Results available

Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

NCT03310632
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Antroquinonol
Drug
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Tampa, Florida • Newnan, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 2 Interventional Results available

Eribulin in HER2 Negative Metastatic BrCa

NCT01827787
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Bangor, Maine • Boston, Massachusetts • Milford, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Nov 2, 2026, 10:47 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

NCT05844293
View directory record Official record
Conditions
FXI
Interventions
FXI-GalNAc-siRNA, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Terminated Phase 2 Interventional Results available

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

NCT02669914
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast, Cancer of the Breast, Gastroesophageal Cancer, Pancreatic Cancer, Cancer of the Pancreas, Colorectal Cancer, Colorectal Carcinoma, Renal Cancer, Kidney Cancer, Cancer of the Kidney, Cancer of Kidney, Ovarian Cancer, Ovary Cancer, Cancer of the Ovary, Cancer of Ovary
Interventions
MEDI4736
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Nov 2, 2026, 10:47 PM EST
Recruiting No phase listed Observational

A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

NCT07635316
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 110 Years
Enrollment
4,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

NCT07287033
View directory record Official record
Conditions
Peanut Allergies
Interventions
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
Drug
Lead sponsor
Mabylon AG
Industry
Eligibility
12 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 2, 2026, 10:47 PM EST
Completed Phase 1Phase 2 Interventional

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

NCT01423058
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
Interventions
Momelotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Nov 2, 2026, 10:47 PM EST